Matches in SemOpenAlex for { <https://semopenalex.org/work/W2937597419> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2937597419 endingPage "ii68" @default.
- W2937597419 startingPage "ii68" @default.
- W2937597419 abstract "Background: LKB1 inactive (LKB1i) lung adenocarcinoma (LA) has an aggressive behavior and is resistant to immunotherapy (IO). LKB1i cells are vulnerable to nutrient starvation. Based on preclinical data showing a synergy cisplatin-metformin, we hypothesized that combining platinum-based chemotherapy (CT) with metformin +/- a calorie-restricted, low-carbohydrate, low-protein diet known as Fasting Mimicking Diet (FMD) may improve the efficacy of CT in patients (pts) with LKB1i LA. Trial design: FAME is a monocentric, open label, double arm, non comparative, randomized, single stage, pick-the-winner phase II trial. Primary objective is Progression Free Survival (PFS), evaluated in comparison with a historical cohort of pts treated with CT. Secondary objectives consist in studying experimental treatment toxicity, response rate, overall survival, metabolic changes in blood, urine and stool, correlation between LKB1 mutation status and LKB1 protein expression. Main inclusion criteria are: advanced LKB1i LA, absence of EGFR mutations and ALK/ROS1 rearrangements, PDL1 expression < 50%, performance status 0-1. Main exclusion criteria are: body mass index <20 kg/m2, weight loss ≥5% in the previous 3 months, diabetes mellitus, active brain metastases, baseline fasting glucose ≤65 mg/dL, arterial pO2 <70 mmHg, high blood lactates. Eligible pts will be randomized 1:1 to up to 4 cycles of platinum-pemetrexed CT + metformin, or up to 4 cycles of platinum-pemetrexed CT + metformin + FMD. After 4 cycles, stable/responding pts will continue pemetrexed + metformin until progression or toxicity. Forty-one pts per arm will be necessary to identify a 4.4 mos increase in median PFS. Brookmeyer-Crowley test will be used with an α tail of .15 and a power of .8 mos. Assuming a dropout rate of 5%, the number of pts to enroll will be 88. Clinical trial identification: NCT03709147, first posted on 17 October 2018; EudraCT: 2018-000788-95. Legal entity responsible for the study: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Funding: AIRC (Associazione Italiana per la Ricerca sul Cancro) Investigator Grant 2017. Disclosure: All authors have declared no conflicts of interest." @default.
- W2937597419 created "2019-04-25" @default.
- W2937597419 creator A5003629519 @default.
- W2937597419 creator A5005810267 @default.
- W2937597419 creator A5009935310 @default.
- W2937597419 creator A5010972450 @default.
- W2937597419 creator A5011289747 @default.
- W2937597419 creator A5013009758 @default.
- W2937597419 creator A5013556082 @default.
- W2937597419 creator A5016191595 @default.
- W2937597419 creator A5027149352 @default.
- W2937597419 creator A5037648798 @default.
- W2937597419 creator A5047481473 @default.
- W2937597419 creator A5059331102 @default.
- W2937597419 creator A5061100797 @default.
- W2937597419 creator A5073304463 @default.
- W2937597419 creator A5074436993 @default.
- W2937597419 creator A5079904438 @default.
- W2937597419 creator A5081585114 @default.
- W2937597419 creator A5089167013 @default.
- W2937597419 creator A5091509029 @default.
- W2937597419 creator A5091714925 @default.
- W2937597419 date "2019-04-01" @default.
- W2937597419 modified "2023-10-18" @default.
- W2937597419 title "Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial" @default.
- W2937597419 doi "https://doi.org/10.1093/annonc/mdz063.086" @default.
- W2937597419 hasPublicationYear "2019" @default.
- W2937597419 type Work @default.
- W2937597419 sameAs 2937597419 @default.
- W2937597419 citedByCount "0" @default.
- W2937597419 crossrefType "journal-article" @default.
- W2937597419 hasAuthorship W2937597419A5003629519 @default.
- W2937597419 hasAuthorship W2937597419A5005810267 @default.
- W2937597419 hasAuthorship W2937597419A5009935310 @default.
- W2937597419 hasAuthorship W2937597419A5010972450 @default.
- W2937597419 hasAuthorship W2937597419A5011289747 @default.
- W2937597419 hasAuthorship W2937597419A5013009758 @default.
- W2937597419 hasAuthorship W2937597419A5013556082 @default.
- W2937597419 hasAuthorship W2937597419A5016191595 @default.
- W2937597419 hasAuthorship W2937597419A5027149352 @default.
- W2937597419 hasAuthorship W2937597419A5037648798 @default.
- W2937597419 hasAuthorship W2937597419A5047481473 @default.
- W2937597419 hasAuthorship W2937597419A5059331102 @default.
- W2937597419 hasAuthorship W2937597419A5061100797 @default.
- W2937597419 hasAuthorship W2937597419A5073304463 @default.
- W2937597419 hasAuthorship W2937597419A5074436993 @default.
- W2937597419 hasAuthorship W2937597419A5079904438 @default.
- W2937597419 hasAuthorship W2937597419A5081585114 @default.
- W2937597419 hasAuthorship W2937597419A5089167013 @default.
- W2937597419 hasAuthorship W2937597419A5091509029 @default.
- W2937597419 hasAuthorship W2937597419A5091714925 @default.
- W2937597419 hasBestOaLocation W29375974191 @default.
- W2937597419 hasConcept C126322002 @default.
- W2937597419 hasConcept C141071460 @default.
- W2937597419 hasConcept C143998085 @default.
- W2937597419 hasConcept C2776256026 @default.
- W2937597419 hasConcept C2776694085 @default.
- W2937597419 hasConcept C2777240266 @default.
- W2937597419 hasConcept C2778239845 @default.
- W2937597419 hasConcept C2779306644 @default.
- W2937597419 hasConcept C2780323712 @default.
- W2937597419 hasConcept C2780739268 @default.
- W2937597419 hasConcept C2781451048 @default.
- W2937597419 hasConcept C71924100 @default.
- W2937597419 hasConcept C90924648 @default.
- W2937597419 hasConceptScore W2937597419C126322002 @default.
- W2937597419 hasConceptScore W2937597419C141071460 @default.
- W2937597419 hasConceptScore W2937597419C143998085 @default.
- W2937597419 hasConceptScore W2937597419C2776256026 @default.
- W2937597419 hasConceptScore W2937597419C2776694085 @default.
- W2937597419 hasConceptScore W2937597419C2777240266 @default.
- W2937597419 hasConceptScore W2937597419C2778239845 @default.
- W2937597419 hasConceptScore W2937597419C2779306644 @default.
- W2937597419 hasConceptScore W2937597419C2780323712 @default.
- W2937597419 hasConceptScore W2937597419C2780739268 @default.
- W2937597419 hasConceptScore W2937597419C2781451048 @default.
- W2937597419 hasConceptScore W2937597419C71924100 @default.
- W2937597419 hasConceptScore W2937597419C90924648 @default.
- W2937597419 hasLocation W29375974191 @default.
- W2937597419 hasOpenAccess W2937597419 @default.
- W2937597419 hasPrimaryLocation W29375974191 @default.
- W2937597419 hasRelatedWork W1481820868 @default.
- W2937597419 hasRelatedWork W2013653877 @default.
- W2937597419 hasRelatedWork W2066950280 @default.
- W2937597419 hasRelatedWork W2358450743 @default.
- W2937597419 hasRelatedWork W2378767654 @default.
- W2937597419 hasRelatedWork W2381460883 @default.
- W2937597419 hasRelatedWork W2471989939 @default.
- W2937597419 hasRelatedWork W2603922820 @default.
- W2937597419 hasRelatedWork W3032772405 @default.
- W2937597419 hasRelatedWork W4302319510 @default.
- W2937597419 hasVolume "30" @default.
- W2937597419 isParatext "false" @default.
- W2937597419 isRetracted "false" @default.
- W2937597419 magId "2937597419" @default.
- W2937597419 workType "article" @default.